Haemangioma: Clinical course, complications and management

British Journal of Dermatology

Volumn 169, Issue 1, 2013, Pages 20-30

  Luu, M ^a   Frieden, I J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACITRACIN; BECAPLERMIN; CEFALEXIN; CLOBETASOL; CORTICOSTEROID; IMIQUIMOD; LIDOCAINE; METRONIDAZOLE; PARACETAMOL; PROPRANOLOL; PSEUDOMONIC ACID; TIMOLOL; XIPAMIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DERMATOLOGICAL AGENT;

BRADYCARDIA; CAPILLARY HEMANGIOMA; CELL PROLIFERATION; DRUG INDUCED CANCER; FUNCTIONAL DISEASE; HEMANGIOMA; HUMAN; HYPOGLYCEMIA; HYPOTENSION; LIVER HEMANGIOMA; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PULSED DYE LASER; REVIEW; SCAR FORMATION; SEIZURE; SKIN HEMANGIOMA; SLEEP DISORDER; TUMOR GROWTH; ULCER; WOUND CARE; WOUND HEALING; CICATRIX; COMPLICATION; CONGENITAL ABNORMALITIES; INTRADERMAL DRUG ADMINISTRATION; PATHOLOGY; SKIN NEOPLASMS; SKIN ULCER;

ADMINISTRATION, CUTANEOUS; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-ANTAGONISTS; CICATRIX; CONGENITAL ABNORMALITIES; DERMATOLOGIC AGENTS; HEMANGIOMA; HUMANS; PROPRANOLOL; SKIN NEOPLASMS; SKIN ULCER;

EID: 84879926335     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12436     Document Type: Review

References (96)

1. Kilcline C, Frieden IJ,. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol 2008; 25: 168-73.
2. Haggstrom AN, Drolet BA, Baselga E, et al,. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 2007; 150: 291-4.
3. Payne MM, Moyer F, Marcks KM, et al,. The precursor to the hemangioma. Plastic Reconstr Surg 1966; 38: 64-7.
4. Hidano A, Nakajima S,. Earliest features of the strawberry mark in the newborn. Br J Dermatol 1972; 87: 138-44.
5. Tollefson MM, Frieden IJ,. Early growth of infantile hemangiomas: what parents' photographs tell us. Pediatrics 2012; 130: e314-20.
6. Chang LC, Haggstrom AN, Drolet BA, et al,. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 2008; 122: 360-7.
7. Suh KY, Frieden IJ,. Infantile hemangiomas with minimal or arrested growth: a retrospective case series. Arch Dermatol 2010; 146: 971-6.
8. Brandling-Bennett HA, Metry DW, Baselga E, et al,. Infantile hemangiomas with unusually prolonged growth phase: a case series. Arch Dermatol 2008; 144: 1632-7.
9. Bauland CG, Luning TH, Smit JM, et al,. Untreated hemangiomas: growth pattern and residual lesions. Plastic Reconstr Surg 2011; 127: 1643-8.
10. Bowers RE, Graham EA, Tomlinson KM,. The natural history of the strawberry nevus. Arch Dermatol 1960; 82: 667-80.
11. Couto RA, Maclellan RA, Zurakowski D, et al,. Infantile hemangioma: clinical assessment of the involuting phase and implications for management. Plastic Reconstr Surg 2012; 130: 619-24.
12. Chamlin SL, Haggstrom AN, Drolet BA, et al,. Multicenter prospective study of ulcerated hemangiomas. J Pediatr 2007; 151: 684-9, 9 e1.
13. Hermans DJ, Boezeman JB, Van de Kerkhof PC, et al,. Differences between ulcerated and non-ulcerated hemangiomas, a retrospective study of 465 cases. Eur J Dermatol 2009; 19: 152-6.
14. Shin HT, Orlow SJ, Chang MW,. Ulcerated haemangioma of infancy: a retrospective review of 47 patients. Br J Dermatol 2007; 156: 1050-2.
15. Maguiness SM, Hoffman WY, McCalmont TH, et al,. Early white discoloration of infantile hemangioma: a sign of impending ulceration. Arch Dermatol 2010; 146: 1235-9.
16. Metz BJ, Rubenstein MC, Levy ML, et al,. Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor. Arch Dermatol 2004; 140: 867-70.
17. Sugarman JL, Mauro TM, Frieden IJ,. Treatment of an ulcerated hemangioma with recombinant platelet-derived growth factor. Arch Dermatol 2002; 138: 314-16.
18. Frieden IJ,. Addendum: commentary on becaplermin gel (Regranex) for hemangiomas. Pediatr Dermatol 2008; 25: 590.
19. David LR, Malek MM, Argenta LC,. Efficacy of pulse dye laser therapy for the treatment of ulcerated haemangiomas: a review of 78 patients. Br J Plast Surg 2003; 56: 317-27.
20. Kim HJ, Colombo M, Frieden IJ,. Ulcerated hemangiomas: clinical characteristics and response to therapy. J Am Acad Dermatol 2001; 44: 962-72.
21. Morelli JG, Tan OT, Weston WL,. Treatment of ulcerated hemangiomas with the pulsed tunable dye laser. Am J Dis Child 1991; 145: 1062-4.
22. Hong E, Fischer G,. Propranolol for recalcitrant ulcerated hemangioma of infancy. Pediatr Dermatol 2012; 29: 64-7.
23. Kim LH, Hogeling M, Wargon O, et al,. Propranolol: useful therapeutic agent for the treatment of ulcerated infantile hemangiomas. J Pediatr Surg 2011; 46: 759-63.
24. Saint-Jean M, Léauté-Labrèze C, Mazereeuw-Hautier J, et al,. Propranolol for treatment of ulcerated infantile hemangiomas. J Am Acad Dermatol 2011; 64: 827-32.
25. Hermans DJ, van Beynum IM, Schultze Kool LJ, et al,. Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. J Am Acad Dermatol 2011; 64: 833-8.
26. Cante V, Pham-Ledard A, Imbert E, et al,. First report of topical timolol treatment in primarily ulcerated perineal haemangioma. Arch Dis Child Fetal Neonatal Ed 2012; 97: F155-6.
27. McMahon P, Oza V, Frieden IJ,. Topical timolol for infantile hemangiomas: putting a note of caution in 'cautiously optimistic'. Pediatr Dermatol 2012; 29: 127-30.
28. Tanner JL, Dechert MP, Frieden IJ,. Growing up with a facial hemangioma: parent and child coping and adaptation. Pediatrics 1998; 101: 446-52.
29. Janmohamed SR, de Waard-van der Spek FB, Madern GC, et al,. Scoring the proliferative activity of haemangioma of infancy: the Haemangioma Activity Score (HAS). Clin Exp Dermatol 2011; 36: 715-23.
30. Haggstrom AN, Beaumont JL, Lai JS, et al,. Measuring the severity of infantile hemangiomas: instrument development and reliability. Arch Dermatol 2012; 148: 197-202.
31. Ceisler EJ, Santos L, Blei F,. Periocular hemangiomas: what every physician should know. Pediatr Dermatol 2004; 21: 1-9.
32. Bramhall RJ, Quaba A,. A review of 58 patients with periorbital haemangiomas to determine appropriate cases for intervention. J Plast Reconstr Aesthet Surg 2008; 61: 138-49.
33. Ranchod TM, Frieden IJ, Fredrick DR,. Corticosteroid treatment of periorbital haemangioma of infancy: a review of the evidence. Br J Ophthalmol 2005; 89: 1134-8.
34. Jalil A, Maino A, Bhojwani R, et al,. Clinical review of periorbital capillary hemangioma of infancy. J Pediatr Ophthalmol Strabismus 2011; 48: 218-25.
35. Schneider D, Lee MS, Harrison AR, et al,. Excision of periorbital hemangiomas to correct visual abnormalities. Arch Facial Plast Surg 2011; 13: 195-8.
36. Ni N, Guo S, Langer P,. Current concepts in the management of periocular infantile (capillary) hemangioma. Curr Opin Ophthalmol 2011; 22: 419-25.
37. El-Essawy R, Galal R, Abdelbaki S,. Nonselective beta-blocker propranolol for orbital and periorbital hemangiomas in infants: a new first-line of treatment? Clin Ophthalmol 2011; 5: 1639-44.
38. Spiteri Cornish K, Reddy AR,. The use of propranolol in the management of periocular capillary haemangioma-a systematic review. Eye (Lond) 2011; 25: 1277-83.
39. Cheng JF, Gole GA, Sullivan TJ,. Propranolol in the management of periorbital infantile haemangioma. Clin Exp Ophthalmol 2010; 38: 547-53.
40. Xue K, Hildebrand GD,. Topical timolol maleate 0.5% for infantile capillary haemangioma of the eyelid. Br J Ophthalmol 2012; 96: 1536-7.
41. Guo S, Ni N,. Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. Arch Ophthalmol 2010; 128: 255-6.
42. Ni N, Langer P, Wagner R, et al,. Topical timolol for periocular hemangioma: report of further study. Arch Ophthalmol 2011; 129: 377-9.
43. Calvo M, Garcia-Millan C, Villegas C, et al,. Topical timolol for infantile hemangioma of the eyelid. Int J Dermatol 2012; 52: 603-4.
44. Javia LR, Zur KB, Jacobs IN,. Evolving treatments in the management of laryngotracheal hemangiomas: will propranolol supplant steroids and surgery? Int J Pediatr Otorhinolaryngol 2011; 75: 1450-4.
45. Denoyelle F, Leboulanger N, Enjolras O, et al,. Role of propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. Int J Pediatr Otorhinolaryngol 2009; 73: 1168-72.
46. Buckmiller L, Dyamenahalli U, Richter GT,. Propranolol for airway hemangiomas: case report of novel treatment. Laryngoscope 2009; 119: 2051-4.
47. Truong MT, Chang KW, Berk DR, et al,. Propranolol for the treatment of a life-threatening subglottic and mediastinal infantile hemangioma. J Pediatr 2010; 156: 335-8.
48. Leboulanger N, Fayoux P, Teissier N, et al,. Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: a preliminary retrospective study of French experience. Int J Pediatr Otorhinolaryngol 2010; 74: 1254-7.
49. Bitar MA, Moukarbel RV, Zalzal GH,. Management of congenital subglottic hemangioma: trends and success over the past 17 years. Otolaryngol Head Neck Surg 2005; 132: 226-31.
50. Vijayasekaran S, White DR, Hartley BE, et al,. Open excision of subglottic hemangiomas to avoid tracheostomy. Arch Otolaryngol Head Neck Surg 2006; 132: 159-63.
51. Horii KA, Drolet BA, Frieden IJ, et al,. Prospective study of the frequency of hepatic hemangiomas in infants with multiple cutaneous infantile hemangiomas. Pediatr Dermatol 2011; 28: 245-53.
52. Dickie B, Dasgupta R, Nair R, et al,. Spectrum of hepatic hemangiomas: management and outcome. J Pediatr Surg 2009; 44: 125-33.
53. Vredenborg AD, Janmohamed SR, de Laat PC, et al,. Multiple cutaneous infantile haemangioma and the risk of internal haemangioma. Br J Dermatol 2013; 169: 188-191.
54. Maguiness SM, Frieden IJ,. Management of difficult infantile haemangiomas. Arch Dis Child 2012; 97: 266-71.
55. Christison-Lagay ER, Burrows PE, Alomari A, et al,. Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry. J Pediatr Surg 2007; 42: 62-7; discussion 7-8.
56. Kulungowski AM, Alomari AI, Chawla A, et al,. Lessons from a liver hemangioma registry: subtype classification. J Pediatr Surg 2012; 47: 165-70.
57. Bessho K, Etani Y, Ichimori H, et al,. Increased type 3 iodothyronine deiodinase activity in a regrown hepatic hemangioma with consumptive hypothyroidism. Eur J Pediatr 2010; 169: 215-21.
58. Metry D, Heyer G, Hess C, et al,. Consensus statement on diagnostic criteria for PHACE syndrome. Pediatrics 2009; 124: 1447-56.
59. Frieden IJ, Reese V, Cohen D,. PHACE syndrome. The association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol 1996; 132: 307-11.
60. Haggstrom AN, Garzon MC, Baselga E, et al,. Risk for PHACE syndrome in infants with large facial hemangiomas. Pediatrics 2010; 126: e418-26.
61. Nabatian AS, Milgraum SS, Hess CP, et al,. PHACE without face? Infantile hemangiomas of the upper body region with minimal or absent facial hemangiomas and associated structural malformations. Pediatr Dermatol 2011; 28: 235-41.
62. Haggstrom AN, Skillman S, Garzon MC, et al,. Clinical spectrum and risk of PHACE syndrome in cutaneous and airway hemangiomas. Arch Otolaryngol Head Neck Surg 2011; 137: 680-7.
63. Siegel DH, Tefft KA, Kelly T, et al,. Stroke in children with posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities (PHACE) syndrome: a systematic review of the literature. Stroke 2012; 43: 1672-4.
64. Metry D, Frieden IJ, Hess C, et al,. Propranolol use in PHACE syndrome with cervical and intracranial arterial anomalies: collective experience in 32 infants. Pediatr Dermatol 2013; 30: 71-89.
65. Drolet BA, Frommelt PC, Chamlin SL, et al,. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013; 131: 128-40.
66. Stockman A, Boralevi F, Taieb A, et al,. SACRAL syndrome: spinal dysraphism, anogenital, cutaneous, renal and urologic anomalies, associated with an angioma of lumbosacral localization. Dermatology 2007; 214: 40-5.
67. Girard C, Bigorre M, Guillot B, et al,. PELVIS syndrome. Arch Dermatol 2006; 142: 884-8.
68. Iacobas I, Burrows PE, Frieden IJ, et al,. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. J Pediatr 2010; 157: 795-801, e1-7.
69. Drolet BA, Chamlin SL, Garzon MC, et al,. Prospective study of spinal anomalies in children with infantile hemangiomas of the lumbosacral skin. J Pediatr 2010; 157: 789-94.
70. Leonardi-Bee J, Batta K, O'Brien C, et al,. Interventions for infantile haemangiomas (strawberry birthmarks) of the skin. Cochrane Database Syst Rev 2011; 5: CD006545.
71. Chakkittakandiyil A, Phillips R, Frieden IJ, et al,. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol 2012; 29: 28-31.
72. Pope E, Chakkittakandiyil A,. Topical timolol gel for infantile hemangiomas: a pilot study. Arch Dermatol 2010; 146: 564-5.
73. Cruz OA, Zarnegar SR, Myers SE,. Treatment of periocular capillary hemangioma with topical clobetasol propionate. Ophthalmology 1995; 102: 2012-15.
74. Senchak AJ, Dann M, Cable B, et al,. Successful treatment of cutaneous hemangioma of infancy with topical imiquimod 5%: a report of 3 cases. Ear Nose Throat J 2010; 89: E21-5.
75. Hazen PG, Carney JF, Engstrom CW, et al,. Proliferating hemangioma of infancy: successful treatment with topical 5% imiquimod cream. Pediatr Dermatol 2005; 22: 254-6.
76. Martinez MI, Sanchez-Carpintero I, North PE, et al,. Infantile hemangioma: clinical resolution with 5% imiquimod cream. Arch Dermatol 2002; 138: 881-4; discussion 4.
77. McCuaig CC, Dubois J, Powell J, et al,. A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. Pediatr Dermatol 2009; 26: 203-12.
78. Hohenleutner S, Badur-Ganter E, Landthaler M, et al,. Long-term results in the treatment of childhood hemangioma with the flashlamp-pumped pulsed dye laser: an evaluation of 617 cases. Lasers Surg Med 2001; 28: 273-7.
79. Rizzo C, Brightman L, Chapas AM, et al,. Outcomes of childhood hemangiomas treated with the pulsed-dye laser with dynamic cooling: a retrospective chart analysis. Dermatol Surg 2009; 35: 1947-54.
80. Batta K, Goodyear HM, Moss C, et al,. Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1-year analysis. Lancet 2002; 360: 521-7.
81. Kessels JP, Hamers ET, Ostertag JU,. Superficial hemangioma: pulsed dye laser versus wait-and-see. Dermatol Surg 2013; 39: 414-21.
82. Witman PM, Wagner AM, Scherer K, et al,. Complications following pulsed dye laser treatment of superficial hemangiomas. Lasers Surg Med 2006; 38: 116-23.
83. Brightman LA, Brauer JA, Terushkin V, et al,. Ablative fractional resurfacing for involuted hemangioma residuum. Arch Dermatol 2012; 148: 1294-8.
84. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al,. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649-51.
85. Hogeling M, Adams S, Wargon O,. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011; 128: e259-66.
86. Izadpanah A, Izadpanah A, Kanevsky J, et al,. Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis. Plast Reconstr Surg 2013; 131: 601-13.
87. Zvulunov A, McCuaig C, Frieden IJ, et al,. Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: a multicenter retrospective study. Pediatr Dermatol 2011; 28: 94-8.
88. Peridis S, Pilgrim G, Athanasopoulos I, et al,. A meta-analysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas. Int J Pediatr Otorhinolaryngol 2011; 75: 455-60.
89. Mazereeuw-Hautier J, Hoeger PH, Benlahrech S, et al,. Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J Pediatr 2010; 157: 340-2.
90. Marqueling AL, Oza V, Frieden IJ, et al,. Propranolol and infantile hemangiomas four years later: a systematic review. Pediatr Dermatol 2013; 30: 182-91.
91. Parikh SR, Darrow DH, Grimmer JF, et al,. Propranolol use for infantile hemangiomas: American Society of Pediatric Otolaryngology Vascular Anomalies Task Force practice patterns. JAMA Otolaryngol Head Neck Surg 2013; 139: 153-6.
92. Bagazgoitia L, Hernandez-Martin A, Torrelo A,. Recurrence of infantile hemangiomas treated with propranolol. Pediatr Dermatol 2011; 28: 658-62.
93. Raphael MF, de Graaf M, Breugem CC, et al,. Atenolol: a promising alternative to propranolol for the treatment of hemangiomas. J Am Acad Dermatol 2011; 65: 420-1.
94. Blanchet C, Nicollas R, Bigorre M, et al,. Management of infantile subglottic hemangioma: acebutolol or propranolol? Int J Pediatr Otorhinolaryngol 2010; 74: 959-61.
95. Pope E, Chakkittakandiyil A, Lara-Corrales I, et al,. Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol. Br J Dermatol 2013; 168: 222-4.
96. Yan AC,. Pain management for ulcerated hemangiomas. Pediatr Dermatol 2008; 25: 586-9.